The role and clinical significance of yes-associated protein 1 in human osteosarcoma

International Journal of Immunopathology and Pharmacology

Volumn 26, Issue 1, 2013, Pages 157-167

  Zhang, Y H ^a   Li, B ^a   Shen, L ^a   Shen, Y ^a   Chen, Xiao Dong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Invasion; Osteosarcoma; Proliferation; Small hairpin RNA; Yes associated protein 1

Indexed keywords

CYCLIN D1; GELATINASE B; ONCOPROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR YAP1;

ADULT; ARTICLE; CANCER STAGING; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; DISTANT METASTASIS; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR MECHANICS; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR INVASION; TUMOR LOCALIZATION; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENNEKING STAGING; GENE SILENCING; GENE TARGETING; HUMAN CELL; MICROARRAY KIT; ONCOGENE; OS MG 63 CELL LINE; OSTEOSARCOMA CELL LINE; TISSUE DISTRIBUTION;

EID: 84881236261     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201302600115     Document Type: Article

References (29)

1. Raymond AK, Ayala AG, Knuutila S. Conventional osteosarcoma. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press 2002; p.264-70.
2. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776-90. (Pubitemid 34111386)
3. Kong C, Hansen MF. Biomarkers in osteosarcoma. Expert Opin Med Diagn 2009; 3:13-23.
4. Tajima Y, Yamazaki K, Makino R, et al. Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic background. Clin Cancer Res 2006; 12:6469-79. (Pubitemid 44799720)
5. Oh H, Irvine KD. Yorkie: the final destination of Hippo signaling. Trends Cell Biol 2010; 20:410-7.
6. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21:2747-61. (Pubitemid 350070721)
7. Zender L, Spector MS, Xue W, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125:1253-67. (Pubitemid 43929093)
8. Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006; 103:12405-410. (Pubitemid 44267272)
9. Guo J, Kleeff J, Zhao Y, et al. Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma. Int J Mol Med. 2006; 17:761-7.
10. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA. Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008; 39:1582-9.
11. Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; 115:4576-85.
12. Hsu JH, Lawlor ER. BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma. Oncogene 2011; 30:2077-85.
13. Hanahan D, Weinberg RA. The hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
14. Orr BA, Bai H, Odia Y, Jain D, Anders RA, Eberhart CG. Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J Neuropathol Exp Neurol 2011; 70:568-77.
15. Muramatsu T, Imoto I, Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis 2011; 32:389-98.
16. Andela VB, Siddiqui F, Groman A, Rosier RN. An immunohistochemical analysis to evaluate an inverse correlation between Runx2/Cbfa1 and NF kappa B in human osteosarcoma. J Clin Pathol 2005; 58:328-30. (Pubitemid 40380335)
17. Olfa G, Christophe C, Philippe L, Romain S, Khaled H, Pierre H, Odile B, Jean-Christophe D. RUNX2 regulates the effects of TNF-alpha on proliferation and apoptosis in SaOs-2 cells. Bone 2010; 46:901-10.
18. Leong DT, Lim J, Goh X, et al. Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Breast Cancer Res 2010; 12:R89.
19. Sadikovic B, Thorner P, Chilton-Macneill S, Martin JW, Cervigne NK, Squire J, Zielenska M. Expression analysis of genes associated with human osteosarcoma rumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer 2010; 10:202.
20. Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL, Lian JB, Stein GS. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 2004; 23:790-9. (Pubitemid 38418746)
21. Lian JB, Stein JL, Stein GS, et al. Runx2/Cbfa1 functions: diverse regulation of gene transcription by chromatin remodeling and co-regulatory protein interactions. Connect Tissue Res 2003; 44:141-8. (Pubitemid 36395436)
22. Stein GS, Lian JB, Stein JL, van Wijnen AJ, Choi JY, Pratap J, Zaidi SK. Temporal and spatial parameters of skeletal gene expression: targeting RUNX factors and their coregulatory proteins to subnuclear domains. Connect Tissue Res 2003; 44:149-53. (Pubitemid 36395437)
23. Vitolo MI, Anglin IE, Mahoney WM Jr, Renoud KJ, Gartenhaus RB, Bachman KE, Passaniti A. The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation. Cancer Biol Ther 2007; 6:856-63. (Pubitemid 351574974)
24. Williams RT, Wu L, Carbonaro-Hall DA, Tolo VT, Hall FL. Identification of a novel cyclin-like protein in human tumor cells. J Biol Chem 1993; 268:8871-80. (Pubitemid 23118679)
25. Benassi MS, Molendini L, Gamberi G, et al. Altered Gl phase regulation in osteosarcoma. Int J Cancer 1997; 74:518-22.
26. Ueda J, Kajita M, Suenaga N, Fujii K, Seiki M. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive rumors. Oncogene 2003; 22:8716-22. (Pubitemid 38010495)
27. Temma T, Sano K, Kuge Y, Kamihashi J, Takai N, Ogawa Y, Saji H. Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors. Biol Pharm Bull 2009; 32:1272-7.
28. Galindo M, Kahler RA, Teplyuk NM, et al. Cell cycle related modulations in Runx2 protein levels are independent of lymphocyte enhancer-binding factor 1 (Lef1) in proliferating osteoblasts. J Mol Histol 2007; 38:501-6. (Pubitemid 350056782)
29. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005; 25:8581-91. (Pubitemid 41369178)